Diagnostics Accelerator to fund projects that develop dementia biomarkers from patient data.
The method purportedly distinguishes patients from controls with more than 90 percent sensitivity and specificity.
A majority of amyloid PET scans led physicians to change how they managed a patient’s disease. The effect on later outcomes is yet to be come.
Among 20 focus areas, 47 research recommendations cover the gamut from basic science to health disparities.
IBM researchers in Australia identify a combination of four proteins in plasma that predicts amyloid positivity in cerebrospinal fluid, and correlates with progression to AD.
A longitudinal study finds that middle-aged people with the highest levels of inflammation markers in their blood succumb to the greatest cognitive decline over the next 20 years.
Among cognitively normal people with amyloid plaques, women have more tau tangles in the entorhinal cortex than do men. Does this indicate susceptibility, or resilience?
In cognitively normal people, a set of blood proteins may predict whether or not amyloid plaques have deposited in a person’s brain.
The FDA has prioritized review of C2N’s blood test for amyloid-β. A pivotal clinical trial will correlate the test with amyloid PET scans.
Studies in mice and humans show that sleep suppresses extracellular tau and slows its spread.
In familial Alzheimer’s disease, rise in NfL in the blood precedes disease onset by 16 years.
Stakeholders have until February 11 to comment on draft FDA guidance for biomarker qualification.
During deep sleep, people with AD pathology, particularly tau tangles, have less low-frequency slow-wave brain activity, which is important for memory consolidation.
The largest study so far to compare brain scans and CSF among African-Americans and Caucasians finds differences, but participant numbers remain small.
The ligand binds the microglia-specific CSF1 receptor in animal and postmortem studies; human trials are forthcoming.